Amplification of the 3q chromosomal region as a specific marker in cervical cancer
Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of w...
Saved in:
Published in | American journal of obstetrics and gynecology Vol. 213; no. 1; pp. 51.e1 - 51.e8 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.07.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0002-9378 1097-6868 1097-6868 |
DOI | 10.1016/j.ajog.2015.02.001 |
Cover
Loading…
Abstract | Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal.
Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus.
Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5–98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive predictive value of 100% (95% CI, 86.7–100%), and a negative predictive value of 98.8% (95% CI, 95.9–99.8), for distinguishing CIN 2,3 from normal.
These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive. |
---|---|
AbstractList | Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal.
Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus.
Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5–98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive predictive value of 100% (95% CI, 86.7–100%), and a negative predictive value of 98.8% (95% CI, 95.9–99.8), for distinguishing CIN 2,3 from normal.
These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive. Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal.OBJECTIVEChromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal.Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus.STUDY DESIGNResidual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus.Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5-98.9%), a specificity of 100% (95% CI, 97.8-100%), a positive predictive value of 100% (95% CI, 86.7-100%), and a negative predictive value of 98.8% (95% CI, 95.9-99.8), for distinguishing CIN 2,3 from normal.RESULTSUsing the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5-98.9%), a specificity of 100% (95% CI, 97.8-100%), a positive predictive value of 100% (95% CI, 86.7-100%), and a negative predictive value of 98.8% (95% CI, 95.9-99.8), for distinguishing CIN 2,3 from normal.These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive.CONCLUSIONThese data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive. Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal. Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus. Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5-98.9%), a specificity of 100% (95% CI, 97.8-100%), a positive predictive value of 100% (95% CI, 86.7-100%), and a negative predictive value of 98.8% (95% CI, 95.9-99.8), for distinguishing CIN 2,3 from normal. These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive. Objective Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix. There are a number of potential clinical uses of testing for 3q gain in liquid cytology specimens, including the identification of subsets of women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology who are at greatest risk of having CIN 2,3 and would thus benefit most from immediate colposcopy. The objective of this study was to establish the sensitivity and specificity of 3q gain for discriminating between CIN 2,3 and normal. Study Design Residual cytology specimens were collected from 199 women. Liquid-based cytology (LBC) was used for the selection of subjects, with women with high-grade squamous intraepithelial lesion or high-grade squamous intraepithelial lesion who had colposcopy and adjudicated biopsy-confirmed CIN 2,3 forming the disease-positive group (n = 28) and women doubly negative for both cytology and high-risk human papillomavirus (hrHPV) testing forming the disease-negative group (n = 171). A single slide was prepared from each residual LBC specimen and analyzed for 3q gain by fluorescent in situ hybridization, using a probe specific for the 3q26 region and a control probe for the chromosome 7 centromere. Two approaches were compared for the determination of 3q gain. The first was based on the analysis of an entire cervical cytology slide for the presence of rare cells with a high copy number (>4 copies) for the 3q locus. The second approach was based on the analysis of 400 cells to determine the percentage with 3 or more copies of the 3q locus. Results Using the approach based on the detection of rare cells with a high copy number (>4 copies) for the 3q locus, 26 of the specimens from women with CIN 2,3 and none of the 171 specimens from women who were both hrHPV and cytology negative was positive for 3q gain. This translates to a sensitivity of 92.9% (95% confidence interval [CI], 76.5–98.9%), a specificity of 100% (95% CI, 97.8–100%), a positive predictive value of 100% (95% CI, 86.7–100%), and a negative predictive value of 98.8% (95% CI, 95.9–99.8), for distinguishing CIN 2,3 from normal. Conclusion These data support the potential clinical use of 3q gain for the evaluation of women in a number of clinical situations, including women with atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and those who are hrHPV positive. |
Author | Wright, Thomas C. Tafas, Triantafyllos Romano, Patricia Grazioli, Vittorio Kilpatrick, Michael W. Verma, Yogita Compagno, John Kershnar, Eric |
Author_xml | – sequence: 1 givenname: Thomas C. surname: Wright fullname: Wright, Thomas C. organization: Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY, and Research Pathology Associates, Irvington, NY – sequence: 2 givenname: John surname: Compagno fullname: Compagno, John organization: West Coast Pathology Laboratories, Hercules, CA – sequence: 3 givenname: Patricia surname: Romano fullname: Romano, Patricia organization: Shiel Medical Laboratory, Brooklyn, NY – sequence: 4 givenname: Vittorio surname: Grazioli fullname: Grazioli, Vittorio organization: Centro Diagnostico Italiano, Milan, Italy – sequence: 5 givenname: Yogita surname: Verma fullname: Verma, Yogita organization: Ikonisys Inc, New Haven, CT – sequence: 6 givenname: Eric surname: Kershnar fullname: Kershnar, Eric organization: Ikonisys Inc, New Haven, CT – sequence: 7 givenname: Triantafyllos surname: Tafas fullname: Tafas, Triantafyllos organization: Ikonisys Inc, New Haven, CT – sequence: 8 givenname: Michael W. surname: Kilpatrick fullname: Kilpatrick, Michael W. email: Michael.kilpatrick@ikonisys.com organization: Ikonisys Inc, New Haven, CT |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25659466$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkl1r3SAch2V0rKfdvsAuhpe7SeZLNDrGoJS9QaHQbtdizD-taRJPNafQbz_taW8K665U_D0_5dEjdLCEBRB6T0lNCZWfxtqO4apmhIqasJoQ-gptKNFtJZVUB2hDCGGV5q06REcpjWXJNHuDDpmQQjdSbtDFybyd_OCdXX1YcBjweg2Y32J3HcMcUpjthCNclU2bsMVpC67k8WzjDUTsF-wg3uWCCTu75Plb9HqwU4J3j-Mx-vP92-_Tn9XZ-Y9fpydnlZNSrZV0jvO244xAT2zTdapvLRBuO8WUBUuEprZrh65vmCDUct3LXquGaQEtt4Ifo4_73m0MtztIq5l9cjBNdoGwS4ZKTYVWvGlz9MNjdNfN0Jtt9Pn69-bJQw6ofcDFkFKEwTi_PihZo_WTocQU5WY0Rbkpyg1hJivPKHuGPrW_CH3ZQ5AF3XmIJjkP2V7vI7jV9MG_jH99hrvJL-UNbuAe0hh2ccnqDTUpA-ayvHz5B1Rkmori7vO_C_53-l-5XcHO |
CitedBy_id | crossref_primary_10_3389_fonc_2022_887139 crossref_primary_10_1111_1759_7714_15045 crossref_primary_10_1186_s12885_016_2739_6 crossref_primary_10_3390_microarrays4020287 crossref_primary_10_1038_s41598_019_45477_5 crossref_primary_10_1080_14737159_2020_1835472 crossref_primary_10_1093_jjco_hyab109 crossref_primary_10_1186_s12916_022_02630_8 crossref_primary_10_1002_gcc_22818 crossref_primary_10_1016_j_currproblcancer_2020_100567 crossref_primary_10_1080_14737159_2016_1217157 crossref_primary_10_1038_s43018_021_00250_4 |
Cites_doi | 10.7326/0003-4819-132-10-200005160-00009 10.1016/j.hrtlng.2013.01.006 10.1016/S0002-9440(10)63498-0 10.1016/j.ygyno.2013.06.005 10.1016/S0140-6736(04)17354-6 10.1097/AOG.0b013e31818f5008 10.1093/jnci/djq562 10.2353/jmoldx.2007.070007 10.1016/j.ygyno.2008.01.040 10.1093/jnci/92.5.397 10.1016/j.ajog.2004.03.055 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y 10.1016/j.ygyno.2009.03.031 10.1002/path.2070 10.1016/S0002-9440(10)62341-3 10.1097/IGC.0b013e31825104bd 10.2353/ajpath.2009.090122 10.1016/S1470-2045(11)70188-7 10.1371/journal.pone.0039101 10.1016/j.ajog.2009.12.016 |
ContentType | Journal Article |
Copyright | 2015 Elsevier Inc. Elsevier Inc. Copyright © 2015 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2015 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2015 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.ajog.2015.02.001 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-6868 |
EndPage | 51.e8 |
ExternalDocumentID | 25659466 10_1016_j_ajog_2015_02_001 S0002937815001155 1_s2_0_S0002937815001155 |
Genre | Journal Article |
GroupedDBID | --- --K --M -ET .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 2KS 354 3O- 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 6J9 7-5 85S 8F7 8P~ AAEDT AAEDW AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYJJ AAYWO ABBQC ABCQX ABDPE ABFNM ABFRF ABJNI ABMAC ABMZM ABOCM ABPMR ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFCHL AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGNAY AGQPQ AGUBO AGYEJ AHDLI AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 C5W CAG COF CS3 EBS EFJIC EFKBS EJD EO8 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IH2 IHE J1W K-O KOM LPU M41 MO0 N4W N9A NEJ NQ- O-L O9- OAUVE OBH OCB OGEVE OHH OHT OMK OQ. OVD P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ RXW SDF SEL SES SEW SJN SPCBC SSH SSZ T5K TAE TEORI TWZ UDS UGJ UHB UHS UHU UKR UNMZH UV1 VH1 VVN WH7 WOQ WOW X6Y X7M XFW YFH YOC YYQ YZZ Z5R ZGI ZXP ZY1 ~G- ~H1 AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AAIAV ABLVK ABYKQ ADOJD AFDAS AHPSJ AJBFU EFLBG G8K LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c668t-6cc337b320ed0a4bb8d7ae03ab828aea0591ab7fbd42501a39d6d984295e73a53 |
IEDL.DBID | .~1 |
ISSN | 0002-9378 1097-6868 |
IngestDate | Thu Jul 10 19:33:51 EDT 2025 Wed Feb 19 02:42:34 EST 2025 Tue Jul 01 00:55:55 EDT 2025 Thu Apr 24 22:59:16 EDT 2025 Fri Feb 23 02:29:19 EST 2024 Sun Feb 23 10:18:58 EST 2025 Tue Aug 26 17:15:27 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | cervical intraepithelial neoplasia grades 2 and 3 low-grade squamous intraepithelial lesion high-risk human papillomavirus 3q gain atypical squamous cells of undetermined significance squamous cell carcinomas high-grade squamous intraepithelial lesion |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2015 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c668t-6cc337b320ed0a4bb8d7ae03ab828aea0591ab7fbd42501a39d6d984295e73a53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 25659466 |
PQID | 1691598347 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_1691598347 pubmed_primary_25659466 crossref_citationtrail_10_1016_j_ajog_2015_02_001 crossref_primary_10_1016_j_ajog_2015_02_001 elsevier_sciencedirect_doi_10_1016_j_ajog_2015_02_001 elsevier_clinicalkeyesjournals_1_s2_0_S0002937815001155 elsevier_clinicalkey_doi_10_1016_j_ajog_2015_02_001 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-07-01 |
PublicationDateYYYYMMDD | 2015-07-01 |
PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | American journal of obstetrics and gynecology |
PublicationTitleAlternate | Am J Obstet Gynecol |
PublicationYear | 2015 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Schiffman, Wentzensen, Wacholder (bib2) 2011; 103 Hopman, Theelen, Hommelberg (bib8) 2006; 210 Jalali, Herzog, Dziura, Walat, Kilpatrick (bib18) 2010; 202 Nanda, McCrory, Myers (bib1) 2000; 132 Luhn, Houldsworth, Cahill (bib15) 2013; 130 Rodolakis, Biliatis, Symiakaki (bib21) 2012; 22 Heselmeyer-Haddad, Janz, Castle (bib14) 2003; 163 Andersson, Sowjanya, Wangsa (bib11) 2009; 175 Heselmeyer-Haddad, Sommerfeld, White (bib10) 2005; 166 Castle, Stoler, Wright, Sharma, Wright, Behrens (bib19) 2011; 12 Heselmeyer, Macville, Schrock (bib7) 1997; 19 Sokolova, Algeciras-Schimnich, Song (bib9) 2007; 9 Kilpatrick, Tafas, Evans (bib17) 2004; 190 Caraway, Khanna, Dawlett (bib6) 2008 Moscicki, Shiboski, Hills (bib3) 2004; 364 Castle, Schiffman, Wheeler, Solomon (bib5) 2009; 113 Parshall (bib16) 2013; 42 Manos, Wright, Lewis (bib13) 1989 Heitmann, Lankachandra, Wall (bib20) 2012; 7 Koutsky (bib4) 2000; 92 Seppo, Jalali, Babkowski (bib12) 2009; 114 Heselmeyer (10.1016/j.ajog.2015.02.001_bib7) 1997; 19 Heselmeyer-Haddad (10.1016/j.ajog.2015.02.001_bib10) 2005; 166 Manos (10.1016/j.ajog.2015.02.001_bib13) 1989 Schiffman (10.1016/j.ajog.2015.02.001_bib2) 2011; 103 Moscicki (10.1016/j.ajog.2015.02.001_bib3) 2004; 364 Seppo (10.1016/j.ajog.2015.02.001_bib12) 2009; 114 Castle (10.1016/j.ajog.2015.02.001_bib19) 2011; 12 Hopman (10.1016/j.ajog.2015.02.001_bib8) 2006; 210 Castle (10.1016/j.ajog.2015.02.001_bib5) 2009; 113 Nanda (10.1016/j.ajog.2015.02.001_bib1) 2000; 132 Jalali (10.1016/j.ajog.2015.02.001_bib18) 2010; 202 Andersson (10.1016/j.ajog.2015.02.001_bib11) 2009; 175 Heitmann (10.1016/j.ajog.2015.02.001_bib20) 2012; 7 Rodolakis (10.1016/j.ajog.2015.02.001_bib21) 2012; 22 Luhn (10.1016/j.ajog.2015.02.001_bib15) 2013; 130 Kilpatrick (10.1016/j.ajog.2015.02.001_bib17) 2004; 190 Sokolova (10.1016/j.ajog.2015.02.001_bib9) 2007; 9 Parshall (10.1016/j.ajog.2015.02.001_bib16) 2013; 42 Caraway (10.1016/j.ajog.2015.02.001_bib6) 2008 Koutsky (10.1016/j.ajog.2015.02.001_bib4) 2000; 92 Heselmeyer-Haddad (10.1016/j.ajog.2015.02.001_bib14) 2003; 163 |
References_xml | – volume: 113 start-page: 18 year: 2009 end-page: 25 ident: bib5 article-title: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2 publication-title: Obstet Gynecol – volume: 9 start-page: 604 year: 2007 end-page: 611 ident: bib9 article-title: Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens publication-title: J Mol Diag – volume: 190 start-page: 1571 year: 2004 end-page: 1581 ident: bib17 article-title: Automated detection of rara fetal cells in maternal blood: eliminating the false-positive XY signals in XX pregnancies publication-title: Am J Obstet Gynecol – volume: 19 start-page: 233 year: 1997 end-page: 240 ident: bib7 article-title: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q publication-title: Genes Chromosom Cancer – volume: 130 start-page: 595 year: 2013 end-page: 600 ident: bib15 article-title: Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results publication-title: Gynecol Oncol – volume: 7 start-page: e39101 year: 2012 ident: bib20 article-title: 3q26 amplification is an effective negative triage test for LSIL: a historical prospective study publication-title: PLoS One – volume: 163 start-page: 1405 year: 2003 end-page: 1416 ident: bib14 article-title: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia publication-title: Am J Pathol – volume: 210 start-page: 412 year: 2006 end-page: 419 ident: bib8 article-title: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer publication-title: J Pathol – volume: 202 start-page: 581.e1 year: 2010 end-page: 581.e5 ident: bib18 article-title: Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding publication-title: Am J Obstet Gynecol – volume: 166 start-page: 1229 year: 2005 end-page: 1238 ident: bib10 article-title: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer publication-title: Am J Pathol – volume: 22 start-page: 742 year: 2012 end-page: 747 ident: bib21 article-title: Role of chromosome 3q26 in predicting progression of cervical dysplasia publication-title: Int J Gynecol Cancer – volume: 364 start-page: 1678 year: 2004 end-page: 1683 ident: bib3 article-title: Regression of low-grade squamous intra-epithelial lesions in young women publication-title: Lancet – volume: 12 start-page: 880 year: 2011 end-page: 890 ident: bib19 article-title: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study publication-title: Lancet Oncol – volume: 175 start-page: 1831 year: 2009 end-page: 1847 ident: bib11 article-title: Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears publication-title: Am J Pathol – volume: 103 start-page: 368 year: 2011 end-page: 383 ident: bib2 article-title: Human papillomavirus testing in the prevention of cervical cancer publication-title: J Natl Cancer Inst – year: 2008 ident: bib6 article-title: Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma publication-title: Gynecol Oncol – volume: 114 start-page: 80 year: 2009 end-page: 83 ident: bib12 article-title: Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix publication-title: Gynecol Oncol – start-page: 209 year: 1989 end-page: 214 ident: bib13 article-title: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses publication-title: Molecular diagnostics of human cancer – volume: 92 start-page: 397 year: 2000 end-page: 402 ident: bib4 article-title: The ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial publication-title: J Natl Cancer Inst – volume: 42 start-page: 221 year: 2013 end-page: 226 ident: bib16 article-title: Unpacking the 2×2 table publication-title: Heart Lung – volume: 132 start-page: 810 year: 2000 end-page: 819 ident: bib1 article-title: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review publication-title: Ann Intern Med – volume: 132 start-page: 810 year: 2000 ident: 10.1016/j.ajog.2015.02.001_bib1 article-title: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review publication-title: Ann Intern Med doi: 10.7326/0003-4819-132-10-200005160-00009 – volume: 42 start-page: 221 year: 2013 ident: 10.1016/j.ajog.2015.02.001_bib16 article-title: Unpacking the 2×2 table publication-title: Heart Lung doi: 10.1016/j.hrtlng.2013.01.006 – volume: 163 start-page: 1405 year: 2003 ident: 10.1016/j.ajog.2015.02.001_bib14 article-title: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)63498-0 – volume: 130 start-page: 595 year: 2013 ident: 10.1016/j.ajog.2015.02.001_bib15 article-title: Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2013.06.005 – volume: 364 start-page: 1678 year: 2004 ident: 10.1016/j.ajog.2015.02.001_bib3 article-title: Regression of low-grade squamous intra-epithelial lesions in young women publication-title: Lancet doi: 10.1016/S0140-6736(04)17354-6 – volume: 113 start-page: 18 year: 2009 ident: 10.1016/j.ajog.2015.02.001_bib5 article-title: Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2 publication-title: Obstet Gynecol doi: 10.1097/AOG.0b013e31818f5008 – volume: 103 start-page: 368 year: 2011 ident: 10.1016/j.ajog.2015.02.001_bib2 article-title: Human papillomavirus testing in the prevention of cervical cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djq562 – volume: 9 start-page: 604 year: 2007 ident: 10.1016/j.ajog.2015.02.001_bib9 article-title: Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens publication-title: J Mol Diag doi: 10.2353/jmoldx.2007.070007 – year: 2008 ident: 10.1016/j.ajog.2015.02.001_bib6 article-title: Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.01.040 – start-page: 209 year: 1989 ident: 10.1016/j.ajog.2015.02.001_bib13 article-title: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses – volume: 92 start-page: 397 year: 2000 ident: 10.1016/j.ajog.2015.02.001_bib4 article-title: The ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.5.397 – volume: 190 start-page: 1571 year: 2004 ident: 10.1016/j.ajog.2015.02.001_bib17 article-title: Automated detection of rara fetal cells in maternal blood: eliminating the false-positive XY signals in XX pregnancies publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2004.03.055 – volume: 19 start-page: 233 year: 1997 ident: 10.1016/j.ajog.2015.02.001_bib7 article-title: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q publication-title: Genes Chromosom Cancer doi: 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y – volume: 114 start-page: 80 year: 2009 ident: 10.1016/j.ajog.2015.02.001_bib12 article-title: Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2009.03.031 – volume: 210 start-page: 412 year: 2006 ident: 10.1016/j.ajog.2015.02.001_bib8 article-title: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer publication-title: J Pathol doi: 10.1002/path.2070 – volume: 166 start-page: 1229 year: 2005 ident: 10.1016/j.ajog.2015.02.001_bib10 article-title: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)62341-3 – volume: 22 start-page: 742 year: 2012 ident: 10.1016/j.ajog.2015.02.001_bib21 article-title: Role of chromosome 3q26 in predicting progression of cervical dysplasia publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e31825104bd – volume: 175 start-page: 1831 year: 2009 ident: 10.1016/j.ajog.2015.02.001_bib11 article-title: Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears publication-title: Am J Pathol doi: 10.2353/ajpath.2009.090122 – volume: 12 start-page: 880 year: 2011 ident: 10.1016/j.ajog.2015.02.001_bib19 article-title: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70188-7 – volume: 7 start-page: e39101 year: 2012 ident: 10.1016/j.ajog.2015.02.001_bib20 article-title: 3q26 amplification is an effective negative triage test for LSIL: a historical prospective study publication-title: PLoS One doi: 10.1371/journal.pone.0039101 – volume: 202 start-page: 581.e1 year: 2010 ident: 10.1016/j.ajog.2015.02.001_bib18 article-title: Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2009.12.016 |
SSID | ssj0002292 |
Score | 2.256563 |
Snippet | Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the cervix.... Objective Chromosome 3q gain has been consistently observed in cervical intraepithelial neoplasia grades 2 and 3 (CIN 2,3) and squamous cell carcinomas of the... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 51.e1 |
SubjectTerms | 3q gain Algorithms Atypical Squamous Cells of the Cervix atypical squamous cells of undetermined significance Cervical Intraepithelial Neoplasia - genetics cervical intraepithelial neoplasia grades 2 and 3 Chromosomes, Human, Pair 3 - genetics DNA Probes Female Gene Dosage high-grade squamous intraepithelial lesion high-risk human papillomavirus Humans In Situ Hybridization, Fluorescence low-grade squamous intraepithelial lesion Obstetrics and Gynecology Precancerous Conditions - genetics Sensitivity and Specificity squamous cell carcinomas Squamous Intraepithelial Lesions of the Cervix - genetics Uterine Cervical Neoplasms - genetics |
Title | Amplification of the 3q chromosomal region as a specific marker in cervical cancer |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0002937815001155 https://www.clinicalkey.es/playcontent/1-s2.0-S0002937815001155 https://dx.doi.org/10.1016/j.ajog.2015.02.001 https://www.ncbi.nlm.nih.gov/pubmed/25659466 https://www.proquest.com/docview/1691598347 |
Volume | 213 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRUJcEG-WR2UkbijUiRM7Oa4qqgXUHhCVerPGj4WtaFI222t_e2cSZxGCFoljkhk5mcyMPyffjAHeBm1cpQqX5RppgZIrk7mQY4ZDdxZHWkOz6qNjvTgpP51WpztwMNXCMK0y5f4xpw_ZOp3ZT9bcv1ituMZX0lxlaoI0jGu40Jy715FPv7_6RfMoiqaYIDBLp8KZkeOFZ903pndVY9_O_KbJ6SbwOUxChw_gfkKPYj7e4EPYie0juHuU_o8_hi9zJogv03c40S0F4Tuhfgr_nWl3fXdO2rwXA13EXqDgQkuWF-dM01mLVSv8kD1IzrNDrJ_AyeGHrweLLO2akHmt602mvVfKOFXIGCSWztXBYJQKHS2uMCLhqRydWbpA4SpzVE3QoalpXqqiUVipp7Dbdm18DsIHr6NcShWMKoP0GOuKAEodlSqxKYsZ5JO5rE8txXlnix924o6dWTaxZRNbWTCBbgbvtjoXY0ONW6XV9BbsVCpKyc1Svr9Vy_xNK_YpPnub254k7R8-NINqq_mbG_5zxDeTi1iKT_7pgm3sLmkk3RBirFVpZvBs9J3tcxPcrLi__4v_HPUl3OOjkT38CnY368v4mjDSxu0NQbAHd-YfPy-OrwGfBg3R |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7RRWp7qeh7Sx-u1FsV4cRxnBxXqGgp7B4qkLhZfm1ZVBLYLP-fmcRZCbVQiWvskZPJPL7E34wBvvlCWSkym6SFwQ-UVKjE-tQkpuvOYlGqa1Y9mxfT0_znmTzbgv2hFoZolTH29zG9i9bxyl7U5t7Vckk1vhxzlSoR0hCukU9gm7pT5SPYnhweTeebgJxlVTagYBKItTM9zctcNL-J4SX71p3pffnpPvzZ5aGDHXgRASSb9Pf4ErZC_QqezuIW-Wv4NSGO-CL-imPNgiHEY-KauXNi3rXNJUrTcQw4aFpmGNVa0nx2SUydFVvWzHUBBOc5sonVGzg9-HGyP03iwQmJK4pynRTOCaGsyHjw3OTWll6ZwIWx-H1lgkFIlRqrFtajx_LUiMoXvioxNcmghJHiLYzqpg7vgTnvisAXXHglcs-dCaVEjFIGIXJT5dkY0kFd2sWu4nS4xR890McuNKlYk4o1z4hDN4bvG5mrvqfGg7PF8Bb0UC2K8U1jyH9QSv1LKrTRRVud6hZn6r_MaAxyI3nHEv-74tfBRDS6KO27mDo0N7hSUSFoLEWuxvCut53NcyPilNTi_8MjV_0Cz6Yns2N9fDg_2oXnNNKTiT_CaL26CZ8QMq3t5-gSt9htEII |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amplification+of+the+3q+chromosomal+region+as+a+specific+marker+in+cervical+cancer&rft.jtitle=American+journal+of+obstetrics+and+gynecology&rft.au=Wright%2C+Thomas+C.&rft.au=Compagno%2C+John&rft.au=Romano%2C+Patricia&rft.au=Grazioli%2C+Vittorio&rft.date=2015-07-01&rft.issn=0002-9378&rft.volume=213&rft.issue=1&rft.spage=51&rft.epage=51.e8&rft_id=info:doi/10.1016%2Fj.ajog.2015.02.001&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ajog_2015_02_001 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029378%2FS0002937814X00098%2Fcov150h.gif |